Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

02-13 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	39.15 $	-3.36%	3,966,686
11/02/26	40.51 $	-3.54%	14,881,712
10/02/26	42.00 $	+0.11%	9,987,839
09/02/26	41.95 $	+2.29%	7,378,820
06/02/26	41.01 $	+0.34%	8,338,793

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate

February 11, 2026 at 11:13 pm

Moderna Falls As FDA Vows To Impose New Vaccine Rules

December 02, 2025 at 04:32 am

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.51USD

Average target price

38.40USD

Spread / Average Target

-5.21%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 02:15:13 13/02/2026 HKT			5-day change	1st Jan Change
39.18 ^USD	-3.27%		-3.82%	+33.30%

08:17pm	PRESS DIGEST-New York Times business news - February 12	RE
02-12	Wall Street gains muted after strong jobs data nibbles at Fed rate cut bets	RE

Capitalization	15.83B 13.34B 12.21B 11.6B 21.51B 1,436B 22.24B 141B 56.22B 691B 59.36B 58.14B 2,427B	P/E ratio 2025 *	-5.14x	P/E ratio 2026 *	-5.94x
Enterprise value	10.98B 9.25B 8.47B 8.04B 14.92B 996B 15.42B 97.64B 38.98B 479B 41.17B 40.32B 1,683B	EV / Sales 2025 *	5.85x	EV / Sales 2026 *	6.38x
Free-Float	90.48%	Yield 2025 *	-	Yield 2026 *	-

08:17pm	PRESS DIGEST-New York Times business news - February 12	RE
02-12	Wall Street gains muted after strong jobs data nibbles at Fed rate cut bets	RE
02-12	S&P 500, Dow muted after jobs data; Alphabet, Microsoft drag on Nasdaq	RE
02-12	Wall Street climbs in broad rally after stronger-than-expected jobs report	RE
02-12	Moderna shares pare losses; last down down 3.8%	RE
02-12	Wall St set to open higher after stronger-than-expected jobs report	RE
02-11	Leerink Partners Adjusts Moderna PT to $12 From $17, Maintains Underperform Rating	MT
02-11	Fda's Vinay Prasad overruled staff to reject Moderna's flu vaccine application - Stat News	RE
02-11	Moderna in a Spin After FDA Declines to Review Flu Vaccine Candidate
02-11	US stock futures stall in run-up to January jobs data	RE
02-11	Goldilocks Jobs, Jittery Markets
02-11	Moderna, Inc. Receives Refusal-To-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, Mrna-1010	CI
02-11	North American Morning Briefing : Futures Mostly Decline; Investors Wait for Jobs Data	DJ

02-11	Leerink Partners Adjusts Moderna PT to $12 From $17, Maintains Underperform Rating	MT
01-31	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
01-29	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
01-29	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
01-24	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT

Moderna, Inc. Stock

Equities

MRNA

US60770K1079

Pharmaceuticals

Valuation: Moderna, Inc.

Chart: Moderna, Inc.

Latest news: Moderna, Inc.

Last Transcript: Moderna, Inc.

Analysts' recommendations: Moderna, Inc.

Press Releases: Moderna, Inc.

News in other languages: Moderna, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Moderna, Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-11	Moderna Stock Alert: - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Moderna Investors - MRNA	NE
02-04	Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.	AQ
01-21	Moderna : Transcript (MRNA USQ Transcript 2026 01 13)	PU
01-13	Moderna : Presentation (Moderna 2026 JPM Presentation 16 FINAL for web upload 78 )	PU
01-12	Moderna : Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference	PU

11:21pm	Wall Street ouvre sans direction claire, attend l'inflation américaine
06:54pm	Moderna unter Druck nach FDA-Entscheidung, Impfstoffkandidaten nicht zu prüfen
03:07pm	Wall Street sans direction claire, les créations d'emplois de janvier dépassent les attentes
02:55pm	MORNING BRIEFING - USA/Asien
02-12	MÄRKTE USA/Knapp behauptet nach überraschend starkem US-Arbeitsmarkt

1 day	-2.84%
1 week	-3.69%
Current month	-10.69%
1 month	+16.31%
3 months	+47.36%
6 months	+53.39%
Current year	+33.47%

1 week	36.66	45.5
1 month	34.05	55.2
Current year	29.81	55.2
1 year	22.28	55.2
3 years	22.28	177.37
5 years	22.28	497.49
10 years	11.54	497.49

Manager	Title	Age	Since
Stéphane Bancel CEO	Chief Executive Officer	54	01/03/2011
James Mock DFI	Director of Finance/CFO	49	06/09/2022
Stephen Hoge PSD	President	50	01/11/2024

Director	Title	Age	Since
Paul Sagan BRD	Director/Board Member	66	01/06/2018
Noubar Afeyan CHM	Chairman	62	01/02/2012
Stéphane Bancel BRD	Director/Board Member	54	01/03/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MODERNA, INC.	-3.09%	-3.69%	+28.90%	-77.05%	15.83B
REGENERON PHARMACEUTICALS, INC.	+0.08%	+2.39%	+18.24%	+2.75%	79.94B
UCB	+3.67%	+2.05%	+43.79%	+249.37%	59.51B
CSL LIMITED	-6.88%	-16.24%	-40.77%	-50.10%	56.08B
SAMSUNG BIOLOGICS CO.,LTD.	+0.41%	+71.90%	+71.90%	+71.90%	54.71B
BIOGEN INC.	+0.85%	+4.35%	+44.96%	-33.41%	28.06B
INNOVENT BIOLOGICS, INC.	-0.67%	+10.42%	+148.05%	+108.06%	19.9B
INCYTE CORPORATION	+2.02%	-2.72%	+44.78%	+24.84%	19.67B
SWEDISH ORPHAN BIOVITRUM AB	+0.59%	+6.10%	+28.07%	+67.93%	15.86B
BRIDGEBIO PHARMA, INC.	+7.35%	+22.55%	+144.44%	+573.86%	14.13B
Average	+0.42%	+0.93%	+53.24%	+93.82%	36.37B
Weighted average by Cap.	-0.11%	-0.20%	+37.79%	+71.09%

	2025 *	2026 *
Net sales	1.88B 1.58B 1.45B 1.38B 2.55B 170B 2.64B 16.7B 6.67B 81.91B 7.04B 6.9B 288B	2.04B 1.72B 1.58B 1.5B 2.78B 186B 2.87B 18.19B 7.26B 89.22B 7.67B 7.51B 313B
Net income	-3.02B -2.55B -2.33B -2.22B -4.11B -274B -4.25B -26.9B -10.74B -132B -11.34B -11.11B -464B	-2.66B -2.24B -2.05B -1.95B -3.61B -241B -3.73B -23.63B -9.44B -116B -9.96B -9.76B -407B
Net Debt	-4.85B -4.09B -3.74B -3.56B -6.59B -440B -6.82B -43.16B -17.23B -212B -18.2B -17.82B -744B	-2.77B -2.34B -2.14B -2.03B -3.77B -252B -3.9B -24.68B -9.85B -121B -10.41B -10.19B -425B